Blog
RSS FeedPosted by Michael Wonder on 01 Sep 2025
Care for people with rare and less common cancers ‘delayed and fragmented’, new report reveals
1 September 2025 - A national survey of nearly 2,500 people affected by cancer has found those with a rare ...
Posted by Michael Wonder on 25 Aug 2025
Bewildering PBAC decision a missed opportunity to ensure Australian cancer patients not left behind
23 August 2025 - MSD Australia & New Zealand is astonished that after eight years of dialogue and consideration, the ...
Posted by Michael Wonder on 25 Aug 2025
Committee rejects application for medication Keytruda to be subsidised for Aussies with cancer
23 August 2025 - Australians with rare cancers like Natalie Willacy have just been handed a devastating hit, which could leave ...
Posted by Michael Wonder on 22 Aug 2025
Breakthrough life-extending combination treatment for advanced bladder cancer recommended by NICE
21 August 2025 - NICE has recommended a new first-line treatment for adults with advanced bladder cancer, marking a significant ...
Posted by Michael Wonder on 06 Aug 2025
NICE approves first immunotherapy combination for endometrial cancer
6 August 2025 - Around 2,100 people with advanced womb cancer are set to benefit from a groundbreaking new treatment option, ...
Posted by Michael Wonder on 01 Aug 2025
Serplulimab in combination with carboplatin and etoposide phosphate for the first-line treatment of patients with extensive-stage small-cell lung cancer
30 July 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 01 Aug 2025
Norgine welcomes PBS listing in Australia of Ifinwil (eflornithine) for patients with high-risk neuroblastoma
1 August 2025 - Approximately 50 children in Australia are diagnosed with neuroblastoma each year, with nearly half classified as having ...
Posted by Michael Wonder on 01 Aug 2025
Dostarlimab in combination with platinum-based chemotherapy for the treatment of patients with advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency
30 July 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 31 Jul 2025
Glofitamab in combination with gemcitabine hydrochloride and oxaliplatin for the treatment of patients with relapsed or refractory diffuse large Bcell lymphoma
29 July 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 25 Jul 2025
Lisocabtagene maraleucel in follicular lymphoma: mysterious study discontinuation
15 July 2025 - The BMS has not provided any study data suitable for early benefit assessment. It initiated a randomised ...
Posted by Michael Wonder on 20 Jul 2025
Amivantamab in combination with lazertinib for the first-line treatment of patients with advanced EGFR mutation positive non-small cell lung cancer
4 July 2025 - The Department of Health and Social Care has NICE to produce guidance on the use of ...
Posted by Michael Wonder on 17 Jul 2025
Thousands more breast cancer patients to benefit from new NHS treatment
17 July 2025 - NICE approves ribociclib combination therapy to help prevent cancer returning in early stage disease. ...
Posted by Michael Wonder on 13 Jul 2025
Zanubrutinib for the treatment of patients with relapsed or refractory mantle cell lymphoma
10 July 2025 - NICE has published final evidence-based recommendations on the use of zanubrutinib for the treatment of adults ...
Posted by Michael Wonder on 02 Jul 2025
Life-saving breast cancer drug now cheaper thanks to expansion of the PBS
1 July 2025 - A potentially life-saving treatment for early-stage breast cancer will become much more affordable for hundreds of ...
Posted by Michael Wonder on 02 Jul 2025
Adagrasib for adults with previously treated, advanced, KRAS G12C mutation positive non-small-cell lung cancer
2 July 2025 - NICE is unable to make a recommendation on the use of adagrasib (Krazati) for the second-line treatment ...